Full Press Release Details
Vancouver, Canada, July 20, 2026 (GLOBE NEWSWIRE) --ClearmindMedicine Inc.(“Clearmind”)(Nasdaq: CMND), a clinical-stage biotechnology company pioneeringnonhallucinogenicneuroplastogen-derived treatments for Alcohol Use Disorder (“AUD”), addiction, and weight management,today announced the filing of a patent application with the Hong Kong Patent Office for innovative psychedelic compounds targeting the treatment of Post-Traumatic Stress Disorder (“PTSD”) and other mental health disorders.
The Hong Kong patent application forms part of Clearmind’s exclusive worldwide licensing agreement with Yissum Research Development Company of the Hebrew University of Jerusalem (“Yissum”). Under the terms of the licensing agreement, Clearmind holds exclusive global rights to develop, manufacture, and commercialize novel compounds developed at Yissum. Clearmind is responsible for advancing the development program in accordance with regulatory requirements.
According to recent market reports, the global PTSDtreatment market is valued at approximately USD 18.5 billion in 2025 and is projected to reach USD 30.2 billion by 2035, growing at a CAGR of 5.0%.
This filing further strengthensClearmind’sposition as aninnovator with a rapidly expanding global IP portfolio.Clearmindbelieves theAsian market-represents a major commercial opportunity, and securing patent protection in Hong Kong provides a strategic gateway for regional market access. ThisfilingenhancesClearmind’sestablished patent coverage in the United States, Europe, and other key jurisdictionsandreinforcing the Company’s long-term value creation strategy.
AboutClearmindMedicine Inc.
Clearmindis a clinical-stageneuroplastogenspharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation,neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.
The Company’s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Shares ofClearmindare listed for trading on Nasdaq under the symbol “CMND.”
For further information, visit:https://www.clearmindmedicine.comor contact:
Investor Relations
Forward-Looking Statements:
This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discussesitsrapidly expanding global IP portfolio,the expected growth of theglobal post-traumatic stress disorder (PTSD) treatment market,its belief thattheAsian marketrepresents a major commercial opportunity, and securing patent protection in Hong Kong provides a strategic gateway for regional market accessand theCompany’s long-term value creation strategy.The Company cannot assure that any patent willissueas a result ofa pending patent application or, if issued, whether it will issue in a form that will be advantageous to the Company.Forward-looking statements are not historical facts, and are based upon management’s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.Such expectations, beliefs and projections are expressed in good faith. However, there can be no assurance that management’s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference ismade to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report on Form 20-F for the fiscal year ended October 31,2025and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements toreflectactual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should bedrawnthat the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release.Clearmindis not responsible for the contents of third-party websites.